|Description:||1. Licochalcone B and Licochalcone D,isolated from Glycyrrhiza, can significantly inhibit LPS-induced phosphorylation at serine 276 and transcriptional activation of NF-KB, they have anti-inflammatory activity. |
2. Licochalcone B can inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model, it significantly inhibits cell lines proliferation in a concentration-dependent and time-dependent manner, these findings provide support for the use of l Licochalcone B in chemoprevention and bladder cancer therapy.
3. Licochalcone B has antimetastatic effects on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity.
4. Licochalcone B can protect the liver from carbon tetrachloride (CCl4)-induced injury, the protection may be due to inhibition of p38 and NFκB signaling, which subsequently reduces inflammation in the liver.
5. Licochalcone B has cardioprotective effects against ischemia/reperfusion in isolated rat hearts, the effects may be attributed to its antioxidant, antiapoptotic, and anti-inflammatory activities.
|Targets:||CDK | PARP | Bcl-2/Bax | p38MAPK | Caspase | MMP(e.g.TIMP) | NF-kB | p65 | AP-1 | IkB | TNF-α | PKA | NO | ROS | IL Receptor | IKK|
|Source:||The roots of Glycyrrhiza glabra L.|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||3.4931 mL||17.4654 mL||34.9308 mL||69.8617 mL||87.3271 mL|
|5 mM||0.6986 mL||3.4931 mL||6.9862 mL||13.9723 mL||17.4654 mL|
|10 mM||0.3493 mL||1.7465 mL||3.4931 mL||6.9862 mL||8.7327 mL|
|50 mM||0.0699 mL||0.3493 mL||0.6986 mL||1.3972 mL||1.7465 mL|
|100 mM||0.0349 mL||0.1747 mL||0.3493 mL||0.6986 mL||0.8733 mL|
Food Chem Toxicol. 2014 Mar;65:242-51.
|Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis.[Pubmed: 24384411]|
|To examine the mechanisms by which Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. Exposure of T24 or EJ cells to LCB significantly inhibited cell lines proliferation in a concentration-dependent and time-dependent manner, and resulted in S phase arrest in T24 or EJ cells, respectively. LCB treatment decreased the expression of cyclin A, cyclin-dependent kinase (CDK1 and CDK2) mRNA, cell division cycle 25 (Cdc25A and Cdc25B) protein. In addition, LCB treatment down-regulated Bcl-2 and survivin expression, enhanced Bax expression, activated caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) protein. Consistently, the tumorigenicity of LCB-treated MB49 cells was limited significantly by using the colony formation assay in vitro and the MB49 tumor model performed in C57BL/6 mice in vivo. These findings provide support for the use of LCB in chemoprevention and bladder cancer therapy.|
Chem Biol Interact. 2014 Oct 29;224C:142-148.
|(E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one, a novel licochalcone B derivative compound, suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice.[Pubmed: 25451593]|
|Activated macrophages mediate inflammation, as they release nitric oxide and pro-inflammatory cytokines in various inflammatory diseases. Suppressing macrophage activation may alleviate inflammatory processes. Here, we report that (E)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (DDP), a novel Licochalcone B derivative compound, inhibits inflammatory reactions in macrophages and protects mice from endotoxin shock. In vitro experiments showed that DDP suppressed the generation of nitric oxide and pro-inflammatory cytokines by suppressing the activation of nuclear factor-κB and activator protein-1 and simultaneously inhibited its upstream inflammatory signaling cascades in lipopolysaccharide in RAW264.7 cells. In an animal model, DDP protected BALB/c mice from lipopolysaccharide-induced endotoxin shock, possibly through inhibition of the production of inflammatory cytokines. DDP inhibited the production of inflammatory mediators and may be a potential target for treatment of various inflammatory diseases.|
Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):527-33.
|Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity.[Pubmed: 25099010]|
|This study investigated the mechanisms by which Licochalcone B (LCB) inhibits the adhesion,invasion and metastasis of human malignant bladder cancer T24 cells. Cell viability was evaluated using a sulforhodamine B (SRB) assay. Cell migration and invasion ability were conducted using wound-healing assay and matrigel transwell invasion assay. The activities of matrix metalloproteinases (MMP)-2 and MMP-9 were measured by gelatin zymography protease assays. The expression in protein level of NF-κBP65 and AP-1 was determined using the ELISA method; the protein levels of MMP-9, NF-κBP65, IκBα and P-IκBα were detected by Western blot. The expression in mRNA level of MMP-9 was assessed using quantitative real-time polymerase chain reaction (PCR) and reverse transcription PCR. The results indicated that Licochalcone Battenuated T24 cell migration, adhesion and invasion in a concentration-dependent manner. Licochalcone B treatment down-regulated the mRNA expression, protein expression and activity of MMP-9 but had no effect on MMP-2. In addition, Licochalcone B treatment decreased the protein level of NF-кBP65 and nuclear translocation of NF-кB. These findings suggested that Licochalcone Battenuated migration of bladder cancer T24 cells and adhesion and invasion accompanied with down-regulated protein expression of MMP-9 and the nuclear translocation of NF-кB. Our results provide support that LCB may be a potent adjuvant therapeutic agent in the prevention and therapy of bladder cancer.|
Int Immunopharmacol. 2009 Apr;9(4):499-507.
|Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway.[Pubmed: 19291859]|
|Licorice root has been used as a traditional medicine for the treatment of gastric ulcer, bronchial asthma and inflammation. Licochalcone A is a major component of Xinjiang licorice, Glycyrrhiza inflata. Previously we showed that Licochalcone A significantly inhibited LPS-induced NF-kappaB transcriptional activation by abrogating the phosphorylation of NF-kappaB p65 at serine 276. Glycyrrhiza inflata contains not only Licochalcone A but also Licochalcone B, Licochalcone C, Licochalcone D, Echinatin and Isoliquiritigenin, harboring the common structure of chalcones. No chalcones had any effect on LPS-induced IkappaB degradation, nuclear translocation and DNA binding activity of NF-kappaB p65; however, we observed that Licochalcone B and Licochalcone D significantly inhibited LPS-induced phosphorylation at serine 276 and transcriptional activation of NF-kappaB, the same as Licochalcone A. Interestingly, we also found that Licochalcone A, Licochalcone B and Licochalcone D effectively inhibited LPS-induced activation of PKA, which is required for the phosphorylation of NF-kappaB p65 at serine 276. Consequently, Licochalcone B and Licochalcone D significantly reduced the LPS-induced production of NO, TNFalpha and MCP-1. On the other hand, Licochalcone C, Echinatin and Isoliquitigenin failed to inhibit LPS-induced NF-kappaB activation. These findings suggest that the anti-inflammatory effect of Glycyrrhiza inflata is ascribable to the potent inhibition of NF-kappaB by Licochalcone A, Licochalcone B and Licochalcone D.|
Iran J Basic Med Sci. 2016 Aug;19(8):910-5.
|Hepatoprotective effects of licochalcone B on carbon tetrachloride-induced liver toxicity in mice.[Pubmed: 27746874 ]|
|The objective of this study was to investigate the hepatoprotective effect of Licochalcone B (LCB) in a mice model of carbon tetrachloride (CCl4)-induced liver toxicity. RESULTS: CCl4-induced hepatotoxicity was manifested by an increase in the levels of ALT, AST, MDA, IL-6, CRP, and TNF-ɑ, and a decrease in the SOD level and GSH/GSSG ratio in the serum. The histopathological examination of the liver sections revealed necrosis and inflammatory reactions. Pretreatment with LCB decreased the levels of ALT, AST, MDA, GSSG, IL-6, CRP, TNF-ɑ, and the protein expression of p38 and NF-κB, increased the level of SOD and GSH, and normalized the hepatic histo-architecture. CONCLUSION: LCB protected the liver from CCl4-induced injury. Protection may be due to inhibition of p38 and NFκB signaling, which subsequently reduced inflammation in the liver.|
Oxid Med Cell Longev. 2014;2014:134862.
|Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts.[Pubmed: 25215172]|
|The generation of reactive oxygen species (ROS) is a major cause of heart injury induced by ischemia-reperfusion. The left ventricular developed pressure (LVDP) and the maximum up/down rate of left ventricular pressure (±dp/dt(max)) were documented by a physiological recorder. Myocardial infarct size was estimated macroscopically using 2,3,5-triphenyltetrazolium chloride staining. Coronary effluent was analyzed for lactate dehydrogenase (LDH) and creatine kinase (CK) release to assess the degree of cardiac injury. The levels of C-reactive protein (CRP), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were analyzed to determine the inflammation status of the myocardial tissue. Cardiomyocyte apoptosis analysis was performed using the In Situ Cell Death Detection Kit, POD. Accordingly, Licochalcone B pretreatment improved the heart rate (HR), increased LVDP, and decreased CK and LDH levels in coronary flow. SOD level and GSH/GSSG ratio increased, whereas the levels of MDA, TNF-α, and CRP and activities of IL-8 and IL-6 decreased in Licochalcone B-treated groups. The infarct size and cell apoptosis in hearts from Licochalcone B-treated group were lower than those in hearts from the I/R control group. Therefore, the cardioprotective effects of Licochalcone B may be attributed to its antioxidant, antiapoptotic, and anti-inflammatory activities.|